

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Guan Chao Holdings Limited

冠轆控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1872)

VOLUNTARY ANNOUNCEMENT BUSINESS UPDATES

This announcement is issued by Guan Chao Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) voluntarily to provide the shareholders (the “**Shareholders**”) and potential investors of the Company with an update on the latest business development of the Group.

Reference is made to the announcements issued by the Company on 26 May 2025 and 4 August 2025 regarding the Group’s newly developed hair product business (the “**Announcements**”). Unless otherwise defined, capitalised terms used in this announcement shall have the same meanings as those defined in the Announcements.

The Company is pleased to provide an update for its shareholders and potential investors that on 9 September 2025, GROLAND Inc., a wholly owned subsidiary of BetaMind (which is also a wholly owned subsidiary of the Company), achieved a significant milestone by obtaining a Certificate of Cosmetic Product Listing from Zoop Technical Service (SZ) Co., Ltd., a reputable firm that specializes in product regulation consulting, testing, and certification services.

This certificate verifies that “Groland AquaKine Scalp Serum”, a cosmetic product launched by GROLAND Inc. (the “**Product**”), has been officially listed with the U.S. Food and Drug Administration (“**FDA**”) in compliance with the Federal Food, Drug, and Cosmetic Act, as amended by the Modernization of Cosmetics Regulation Act of 2022 (MoCRA).

This achievement confirms that the Product has met all legal registration requirements necessary for entering the United States (U.S.) market for sale. The Company is dedicated to ensuring that all relevant products comply with U.S. cosmetic regulations, particularly regarding ingredient safety, Good Manufacturing Practices (GMP), and labelling compliance.

The FDA is the leading regulatory agency for food and drugs worldwide. It oversees important aspects of cosmetic regulation, including product safety, quality assurance, and labelling standards. The successful registration of the Product exemplifies GROLAND Inc.'s strong commitment to upholding high product quality and safety standards. Also, this achievement enhances the Group's ability to offer consumers safer, more reliable, and trustworthy options.

In addition to the above, the two active compounds developed for the hair growth product, XTP-118 and XTP-016, have completed the U.S. Cosmetic Ingredient Review (INCI) registration process, which is overseen by the Personal Care Products Council. This accomplishment enables the cosmetic industry to effectively track the safety and regulatory status of ingredients globally, thereby enhancing its ability to market safe products in alignment with national regulations.

The Company believes that completing the registration process qualifies the products launched by GROLAND Inc. to enter the U.S. market. This milestone establishes a strong foundation for future brand promotion and global expansion efforts.

The Board will make further announcements to inform Shareholders and potential investors of the Company of any material developments in the business operations of the Group, if and when appropriate.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Guan Chao Holdings Limited
Tan Shuay Tarnng Vincent
Co-chairman and executive Director

Hong Kong, 12 November 2025

As at the date of this announcement, the Board comprises Mr. Tan Shuay Tarnng Vincent, Mr. Zhang Xiaoyang, Ms. Beng Lee Ser Marisa and Mr. Jin Zhehui as executive Directors; Ms. Dong Wenying as non-executive Director; and Mr. Chow Wing Tung, Mr. Tam Yat Kin Ken and Mr. Wu Qing as independent non-executive Directors.

* *For identification only*